Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clebopride is a small molecule dopamine antagonist with antiemetic and prokinetic properties, primarily used to treat functional gastrointestinal disorders such as gastroparesis, functional dyspepsia, gastroesophageal reflux disease (GERD), chronic gastritis, non-ulcer dyspepsia, and to prevent or treat nausea and vomiting—including that associated with chemotherapy[1][2][6][10]. Chemically related to metoclopramide, it acts by selectively blocking dopamine D2 receptors in the gastrointestinal tract and central nervous system. This antagonism enhances acetylcholine release via serotonin 5-HT4 receptor agonism in the GI tract, promoting smooth muscle contraction and improving gastric emptying and intestinal transit[8]. Its primary mechanism is focused on restoring normal gut motility. It is not typically used for other medical conditions outside of GI motility disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clebopride.